Premium
Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats
Author(s) -
Khan Md. Abdul Hye,
Hwang Sung Hee,
Barnett Scott D.,
Stavniichuk Anna,
Jankiewicz Wojciech K.,
Hammock Bruce D.,
Imig John D.
Publication year - 2021
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15623
Subject(s) - medicine , enalapril , diabetic nephropathy , endocrinology , nephrin , diabetes mellitus , nephropathy , blood pressure , type 2 diabetes , blood urea nitrogen , kidney , angiotensin converting enzyme , proteinuria , podocyte
Background and Purpose Diabetic nephropathy is a common complications related to high morbidity and mortality in type 2 diabetes. We investigated the action of the dual modulator, PTUPB, a soluble epoxide hydrolase and cyclooxygenase‐2 inhibitor against diabetic nephropathy. Experimental Approach Sixteen‐week‐old type 2 diabetic and proteinuric obese ZSF1 rats were treated with vehicle, PTUPB or enalapril for 8 weeks. Measurements were made of epoxyeicosatrienoic acids, thromboxane B 2 (TBX 2 ) and prostaglandin E2 (PGE 2 ) in the kidney of these and lean ZSF1 rats along with their blood pressure. Key Result Obese ZSF1 rats were diabetic with fivefold higher fasting blood glucose levels and markedly higher HbA1c levels compared with lean ZSF1 rats. PTUPB nor enalapril reduced fasting blood glucose or HbA1c but alleviated the development of diabetic nephropathy. In PTUPB‐treated obese ZSF1 rats, glomerular nephrin expression was preserved. Enalapril also alleviated diabetic nephropathy. Diabetic renal injury in obese ZSF1 rats was accompanied by renal inflammation with six to sevenfold higher urinary MCP‐1 (CCR2) level and renal infiltration of CD‐68 positive cells. PTUPB and enalapril significantly reduced urinary MCP‐1 levels and renal mRNA expression of cytokines. Both PTUPB and enalapril lowered blood pressure. PTUPB but not enalapril decreased hyperlipidaemia and liver injury in obese ZSF1 rats. Conclusion and Implications Overall, the dual modulator PTUPB does not treat hyperglycaemia but can effectively alleviate hypertension, diabetic nephropathy, hyperlipidaemia and liver injury in type 2 diabetic rats. Our data further demonstrate that the renal actions of PTUPB are comparable with a current standard diabetic nephropathy treatment.